SCHEMBL8551647

SCHEMBL8551647

c1ccc(COC2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.64
CARM1 Q86X55 2/20 0.64
PRMT6 Q96LA8 2/20 0.64
HRH3 Q9Y5N1 2/20 0.64
TMEM97 Q5BJF2 1/20 0.64
PRMT8 Q9NR22 1/20 0.64
ACHE P22303 2/20 0.59
DRD2 P14416 1/20 0.58
DRD4 P21917 1/20 0.58
DRD3 P35462 1/20 0.58
CCR3 P51677 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
BCHE P06276 3/20 0.54
BACE1 P56817 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8555397 0.98 SIGMAR1 (0.62) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL7299780 0.91 CARM1 (0.60) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL23972327 0.91 LMNA (0.64) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL24652674 0.90 NPC1 (0.58) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL29079552 0.86 ACHE (0.51) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL23972324 0.85 CARM1 (0.67) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL11403585 0.83 ACHE (0.56) SIGMAR1HRH3ACHEDRD2DRD4
SCHEMBL8646865 0.83 CARM1 (0.64) SIGMAR1CARM1PRMT6HRH3TMEM97
SCHEMBL11009529 0.82 BCHE (0.65) SIGMAR1ACHEDRD2DRD4BCHE
SCHEMBL11226960 0.82 CTSL (0.60) SIGMAR1CARM1PRMT6HRH3TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044216-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION Seqirus UK Limited (GB) 2017-02-16 US disclosed
EP-0871613-A1 BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 1998-10-21 EP disclosed
CN-1183768-A Benzyl piepridine derivs as pharmaceutical agents HOFFMANN LA ROCHE (CH) 1998-06-03 CN disclosed
US-5753679-A SCIZOPHRENIA HOFFMANN-LA ROCHE INC. (US) 1998-05-19 US disclosed
WO-1996035666-A1 BENZYL PIPERIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044216-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION MRPL21, CHLSN, MAX SIGMAR1 4122/4885CARM1 3992/4885PRMT6 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.